Literature DB >> 24072366

Low long-term risk of foot ulcer recurrence after nerve decompression in a diabetes neuropathy cohort.

D Scott Nickerson1, Andrew J Rader.   

Abstract

BACKGROUND: Use of nerve decompression in diabetic sensorimotor polyneuropathy is a controversial treatment characterized as being of unknown scientific effectiveness owing to lack of level I scientific studies.
METHODS: Herein, long-term follow-up data have been assembled on 65 diabetic patients with 75 legs having previous neuropathic foot ulcer and subsequent operative decompression of the common peroneal and tibial nerve branches in the anatomical fibro-osseous tunnels.
RESULTS: The cohort's previously reported low recurrence risk of less than 5% annually at a mean of 2.49 years of follow-up has persisted for an additional 3 years, and cumulative risk is now 2.6% per patient-year. Nine of 75 operated legs (12%) have developed an ulcer in 4,218 months (351 patient-years) of follow-up. Of the 53 contralateral legs without decompression, 16 (30%) have ulcerated, of which three have undergone an amputation. Fifty-nine percent of patients are known to be alive with intact feet a mean of 60 months after decompression.
CONCLUSIONS: The prospective, objective, statistically significant finding of a large, long-term diminution of diabetic foot ulcer recurrence risk after operative nerve decompression compares very favorably with the historical literature and the contralateral legs of this cohort, which had no decompression. This finding invites prospective randomized controlled studies for validation testing and reconsideration of the frequency and contribution of unrecognized nerve entrapments in diabetic sensorimotor polyneuropathy and diabetic foot complications.

Entities:  

Mesh:

Year:  2013        PMID: 24072366     DOI: 10.7547/1030380

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  9 in total

Review 1.  Reconsidering nerve decompression: an overlooked opportunity to limit diabetic foot ulcer recurrence and amputation.

Authors:  D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

Review 2.  Carpal and cubital tunnel and other, rarer nerve compression syndromes.

Authors:  Hans Assmus; Gregor Antoniadis; Christian Bischoff
Journal:  Dtsch Arztebl Int       Date:  2015-01-05       Impact factor: 5.594

3.  Australian guideline on prevention of foot ulceration: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease.

Authors:  Michelle R Kaminski; Jonathan Golledge; Joel W J Lasschuit; Karl-Heinz Schott; James Charles; Jane Cheney; Anita Raspovic
Journal:  J Foot Ankle Res       Date:  2022-07-06       Impact factor: 3.050

4.  Illustration of Cost Saving Implications of Lower Extremity Nerve Decompression to Prevent Recurrence of Diabetic Foot Ulceration.

Authors:  Timothy M Rankin; John D Miller; Angelika C Gruessner; D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2015-06-08

Review 5.  Biologic Basis of Nerve Decompression Surgery for Focal Entrapments in Diabetic Peripheral Neuropathy.

Authors:  John Sessions; D Scott Nickerson
Journal:  J Diabetes Sci Technol       Date:  2014-02-27

Review 6.  Nerve decompression and neuropathy complications in diabetes: Are attitudes discordant with evidence?

Authors:  D Scott Nickerson
Journal:  Diabet Foot Ankle       Date:  2017-09-06

Review 7.  Decompression nerve surgery for diabetic neuropathy: a structured review of published clinical trials.

Authors:  James W Albers; Ryan Jacobson
Journal:  Diabetes Metab Syndr Obes       Date:  2018-09-24       Impact factor: 3.168

8.  Lower Extremity Nerve Decompression for Diabetic Peripheral Neuropathy: A Systematic Review and Meta-analysis.

Authors:  Zahir T Fadel; Wafa M Imran; Turki Azhar
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-08-18

9.  Nerve Decompression and Restless Legs Syndrome: A Retrospective Analysis.

Authors:  James C Anderson; Megan L Fritz; John-Michael Benson; Brian L Tracy
Journal:  Front Neurol       Date:  2017-07-06       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.